Overview

Evaluation of the Bioavailability of Pramlintide

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide
Criteria
Inclusion Criteria:

- HbA1c value between 6-12%

- BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2

- Consistent insulin regimen for 2 months prior to screening